Replies to post #206 on Santarus Inc (SNTS)

[surf1944]

1:17AM Santarus partner Pharming updates on study 1310 and shares in issue (SNTS) 6.87 : Biotech company Pharming Group NV provides a short update from its press release dated June 12, 2012. Study 1310, the Phase III clinical study with RUCONEST that is intended to support the submission of a Biologics License Application to the FDA, continues to recruit with additional patients enrolled this week. Currently 70 of the 75 patients required for the completion of Study 1310 have been treated. RUCONEST is partnered with SNTS in North America where the drug is undergoing Phase III clinical development.